TY - JOUR
T1 - Factors Associated with Health Care Providers' Preference for Forgoing an Oral Lead-In Phase When Initiating Long-Acting Injectable Cabotegravir and Rilpivirine in the SOLAR Clinical Trial
AU - Karver, Tahilin Sanchez
AU - Pascual-Bernaldez, Miguel
AU - Berni, Alessandro
AU - Hnoosh, Ahmed
AU - Castagna, Antonella
AU - Messiaen, Peter
AU - Puerto, Maria Jose Galindo
AU - Bloch, Mark
AU - Adachi, Eisuke
AU - Sinclair, Gary
AU - Felizarta, Franco
AU - Angel, Jonathan B.
AU - Sutton, Kenneth
AU - Sutherland-Phillips, Denise
AU - D'Amico, Ronald
AU - Kerrigan, Deanna
N1 - Funding Information:
This study was funded by ViiV Healthcare.
Publisher Copyright:
© Copyright 2023, Mary Ann Liebert, Inc., publishers 2023.
PY - 2023/1/1
Y1 - 2023/1/1
N2 - Cabotegravir and rilpivirine long-acting (LA) antiretroviral therapy (ART) demonstrated similar safety and efficacy in maintaining viral suppression among participants switching from daily oral to LA ART in the Extension Phase of the FLAIR trial. The Phase IIIb SOLAR study comparing efficacy and safety of daily oral versus LA ART every 2 months allowed participants and health care providers (HCPs) to choose an oral lead-in (OLI) before LA initiation or proceed by immediately starting with injections (SWI). We conducted an online survey among SOLAR HCPs (n = 110) in 13 countries to assess reasons for choosing OLI versus SWI. Logistic regression was used to identify factors influencing this decision. Thirty-two percent of HCPs reported a future preference to use OLI, whereas 54% reported a future preference for SWI. HCPs had greater odds of reporting future intentions for SWI if they were from Continental Europe versus North America [adjusted odds ratio (aOR): 3.83, p < 0.05], from sites with a greater number of participants who initiated LA ART without OLI (aOR: 1.56, p < 0.01), and those who reported comfort with the medication safety profile (aOR: 6.39, p < 0.01). HCPs who participated in LA ART trials before SOLAR had decreased odds of reporting a preference for SWI compared to those with no prior LA ART trial experience (aOR: 0.11; p < 0.01). Results indicated higher intentions to SWI over OLI among HCPs initiating participants on LA ART. A major factor associated with SWI was provider comfort with safety data, reinforcing the role of continued training regarding an SWI approach.
AB - Cabotegravir and rilpivirine long-acting (LA) antiretroviral therapy (ART) demonstrated similar safety and efficacy in maintaining viral suppression among participants switching from daily oral to LA ART in the Extension Phase of the FLAIR trial. The Phase IIIb SOLAR study comparing efficacy and safety of daily oral versus LA ART every 2 months allowed participants and health care providers (HCPs) to choose an oral lead-in (OLI) before LA initiation or proceed by immediately starting with injections (SWI). We conducted an online survey among SOLAR HCPs (n = 110) in 13 countries to assess reasons for choosing OLI versus SWI. Logistic regression was used to identify factors influencing this decision. Thirty-two percent of HCPs reported a future preference to use OLI, whereas 54% reported a future preference for SWI. HCPs had greater odds of reporting future intentions for SWI if they were from Continental Europe versus North America [adjusted odds ratio (aOR): 3.83, p < 0.05], from sites with a greater number of participants who initiated LA ART without OLI (aOR: 1.56, p < 0.01), and those who reported comfort with the medication safety profile (aOR: 6.39, p < 0.01). HCPs who participated in LA ART trials before SOLAR had decreased odds of reporting a preference for SWI compared to those with no prior LA ART trial experience (aOR: 0.11; p < 0.01). Results indicated higher intentions to SWI over OLI among HCPs initiating participants on LA ART. A major factor associated with SWI was provider comfort with safety data, reinforcing the role of continued training regarding an SWI approach.
KW - HIV
KW - clinical trial
KW - long-acting injectable ART
KW - oral lead-in
KW - providers
KW - survey
UR - http://www.scopus.com/inward/record.url?scp=85146139851&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85146139851&partnerID=8YFLogxK
U2 - 10.1089/apc.2022.0168
DO - 10.1089/apc.2022.0168
M3 - Article
C2 - 36626155
AN - SCOPUS:85146139851
SN - 1087-2914
VL - 37
SP - 53
EP - 59
JO - AIDS patient care and STDs
JF - AIDS patient care and STDs
IS - 1
ER -